i2o Therapeutics
- Biotech or pharma, therapeutic R&D
i2o Therapeutics is developing a rich pipeline of once-monthly mono- and combination therapies of GLP-1 receptor agonists, amylin DACRAs and PYY for the treatment of obesity, overweight, type 2 diabetes and other related cardiovascular, renal and metabolic diseases. i2o's highly differentiated assets are designed to optimize PK, delivering improved GI tolerability, allowing more patients to receive the full benefit of the prescribed dose on a once-monthly or even once-quarterly dosing schedule without the need for complicated titration regimens.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}